


UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES
GRADUATE FACULTY APPLICATION

1. Name: Carrie McAdam-Marx, MSCI, Ph.D.
2. UAMS Graduate Program Sponsor: Pharmaceutical Sciences Graduate Program Major field: Pharmaceutical Evaluation & Policy
3. Present UAMS academic title or administrative position: Associate Professor & Director, PEP Division, Pharmacy Practice Dept.
- Date appointed this rank/position: July 2017 Employed by: College of Pharmacy, UAMS

4. Comments of Department Chair/Head or Program Director including: evidence of scholarly development, effectiveness as a teacher, quality of publications and reallocation of duties if this application is approved.


Dr. McAdam-Marx is the new Director of the Pharmaceutical Evaluation & Policy Division of the Pharmacy Practice Department in the College of Pharmacy. As such, she will serve as the PEP-Track Director of the Pharmaceutical Sciences Graduate Program. She has extensive experience in her field, having earned a BS degree in pharmacy followed by a residency and Master's degree in Hospital Pharmacy. She subsequently earned her Ph.D. in Health Policy and completed a Master of Science in Clinical Investigation degree.

Dr. McAdam-Marx has an extensive record of publications in peer-reviewed journals along with an impressive level of extramural funding. She has extensive teaching experience at the professional and graduate level and has served as chair of several doctoral dissertation committees as well as Director of the graduate studies at her most recent position.




Program Director

7/19/17
Date



Graduate Council Representative


I have read the comments of my Program Director and I do, do not (circle one) wish to supply additional information in support of my application.



Applicant's Signature


7-17-17
Date

Approvals




Chair, Graduate Faculty Committee

11/15/17
Date



Chair, Graduate Council

11/15/17
Date



Dean of the Graduate School

11/15/17
Date

5. List your planned involvement in graduate education (courses, theses, dissertations):

Dr. McAdam-Marx will be involved as the leader of the PEP-Track which is one of two tracks composing the Pharmaceutical Sciences Graduate Program. She will work with graduate faculty in this program to develop their skills and to recruit and guide students towards the Master of Science and Doctor of Philosophy degrees.

6. Briefly summarize your experience in graduate-level classroom teaching:

At the University of Utah she has taught graduate level courses including graduate seminar, US healthcare policy, literature evaluation, and an introduction to biostatistics. Please see attached CV for details.

7. Briefly summarize your experience in research and student research mentoring:

She has chaired 1 MS committee and 3 PhD committees as well as serving as a member of 3 additional MS and 1 additional PhD committee.

8. Attach Curriculum Vita showing educational background (including institutions attended, degrees awarded and dates), honors or awards received, scholarly or professional organization affiliations, teaching experience (give school, dates and advanced and graduate subjects taught), including student theses and/or dissertations supervised. Cite publications and research in progress.

Carrie McAdam-Marx, MSCI, PhD, RPh

University of Arkansas for Medical Sciences
Pharmaceutical Evaluation & Policy Division
4301 W. Markham St
Little Rock, AR 72205
501-526-5583 (phone)
CMcAdamMarx@uams.edu

I. EDUCATION

| <u>Years</u> | <u>Degree</u> | <u>Institution (Area of Study)</u> |
|--------------|---------------|--|
| 1983 - 1988 | BS | University of Kansas (Pharmacy) Lawrence, KS |
| 1988 - 1990 | Resident | University of Minnesota Hospitals and Clinics (Hospital Pharmacy PGY2) Minneapolis, MN |
| 1988 - 1991 | Master's | University of Minnesota (Hospital Pharmacy Administration) Minneapolis, MN |
| 2003 - 2009 | PhD | University of the Sciences Philadelphia (Health Policy) Philadelphia, PA |
| 2010 - 2013 | MSCI | University of Utah (Clinical Investigation) Salt Lake City, UT |

II. CURRENT LICENSES & CERTIFICATES

1989 - Present State License (MN) - Pharmacist

III. PROFESSIONAL APPOINTMENTS

| | |
|---------------|---|
| 07/90 - 02/92 | Pharmacy Supervisor, University of Minnesota Hospital and Clinic, Minneapolis, MN |
| 02/92 - 09/93 | Pharmacy Programs Account Manager, Diversified Pharmaceutical Services, Minneapolis, MN |
| 09/93 - 10/95 | Product Development Manager, Diversified Pharmaceutical Services, Minneapolis, MN |
| 10/95 - 12/97 | Product and Business Development Manager, Diversified Health Systems International, London, United Kingdom |
| 12/97 - 12/99 | Operations Manager, Diversified Health Systems (DHS) Australia, Melbourne, Australia |
| 01/00 - 07/01 | Business Development Manager, GlaxoSmithKline, Healthcare Management, Philadelphia, PA |
| 07/01 - 09/04 | Strategic Operations Manager, GlaxoSmithKline, Integrated Healthcare Markets (IHM), Philadelphia, PA |
| 09/04 - 07/05 | Strategic Pricing Manager, GlaxoSmithKline, Strategic Pricing & Contract Management, Philadelphia, PA |

| | |
|---------------|---|
| 10/05 - 12/09 | Research Associate, Adjunct Assistant Professor, University of Utah, Pharmacotherapy Outcomes Research Center, Salt Lake City, UT |
| 07/09 - 06/13 | Research Assistant Professor, University of Utah, Department of Pharmacotherapy, Salt Lake City, UT |
| 07/11 - 06/12 | Pharmacotherapy Outcomes Research Post-Doctoral Fellowship Director, University of Utah, Salt Lake City, UT |
| 07/13 - 06/14 | Research Associate Professor, University of Utah, Department of Pharmacotherapy, Salt Lake City, UT |
| 07/14 - 05/17 | Associate Professor, University of Utah, Department of Pharmacotherapy, Salt Lake City, UT |
| 07/16 - 05/17 | Director of Graduate Studies, University of Utah, Salt Lake City, UT |
| 07/17-Present | Associate Professor & Director, University of Arkansas for Medical Sciences, Pharmaceutical Evaluation & Policy Division, Little Rock, AR |

IV. PUBLICATIONS

A. Peer-Reviewed Journal Articles

1. Asche CV, **McAdam-Marx C**, Shane-McWhorter L, Sheng X, Plauschinat CA (2008). Evaluation of adverse events of oral antihyperglycemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis. *Drugs Aging*, 25(7), 611-22.
2. Asche C, **McAdam-Marx C**, Seal B, Crookston B, Mullins CD (2008). Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance. *J Antimicrob Chemother*, 61(5), 1162-8.
3. Asche CV, **McAdam-Marx C**, Shane-McWhorter L, Sheng X, Plauschinat CA (2008). Association between oral antidiabetic use, adverse events and outcomes in patients with type 2 diabetes. *Diabetes, Obesity and Metabolism Online*, 10(8), 638-45.
4. Brixner D, Ghate SR, **McAdam-Marx C**, Ben-Joseph R, Said Q (2008). Association between cardiometabolic risk factors and body mass index based on diagnosis and treatment codes in an electronic medical record database. *J Manag Care Pharm*, 14(8), 756-67.
5. **McAdam-Marx C**, Ye X, Sung JC, Brixner DI, Kahler KH (2009). Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting. *Clin Ther*, 31(5), 1116-23.
6. Brixner DI, **McAdam-Marx C**, Ye X, Boye KS, Nielsen LL, Wintle M, Misurski D, Fabunmi R (2009). Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. *Diabetes, Obesity and Metabolism Online*, 11(12), 1122-30.
7. **McAdam-Marx C**, Bouchard J, Aagren M, Nelson R, Brixner D (2010). Analysis of glycaemic control and weight change in patients initiated with human or analog insulin in an US ambulatory care setting. *Diabetes, Obesity and Metabolism Online*, 12(1), 54-64.
8. **McAdam-Marx C**, Yu J, Bouchard J, Aagren M, Brixner DI (2010). Comparison of daily insulin dose and other antidiabetic medications usage for type 2 diabetes patients treated with an analog basal insulin. *Curr Med Res Opin*, 26(1), 191-201.

9. **McAdam-Marx C**, Field RI, Metraux S, Moelter ST, Brixner DI (2010). Physician utilization by insurance type among youth with type 2 diabetes. *Am J Manag Care*, 16(1), 55-64.
10. Said Q, McAdam Marx C, Schwartz SJ, Ben-Joseph R, Brixner DI (2010). Impact of Body Mass Index on the Incidence of Cardiometabolic Risk Factors in Ambulatory Care Settings over Five Years or More. *Value Health*, 13(2), 265-272.
11. Said Q, Marx CM, Schwartz JS, Ben-Joseph R, Brixner DI (2010). Impact of body mass index on the incidence of cardiometabolic risk factors in ambulatory care settings over 5 years or more. *Value Health*, 13(2), 265-72.
12. **McAdam-Marx C**, Roland CL, Cleveland J, Oderda GM (2010). Costs of opioid abuse and misuse determined from a Medicaid database. *J Pain Palliat Care Pharmacother*, 24(1), 5-18.
13. Brixner DI, **McAdam-Marx C**, Ye X, Lau H, Munger MA (2010). Assessment of time to follow-up visits in newly-treated hypertensive patients using an electronic medical record database. *Curr Med Res Opin*, 26(8), 1881-91.
14. Asche C, Nelson R, **McAdam-Marx C**, Jhaveri M, Ye X (2010). Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA. *Osteoporos Int*, 21(8), 1427-36.
15. **McAdam-Marx C**, Bouchard J, Aagren M, Conner C, Brixner DI (2011). Concurrent control of blood glucose, body mass, and blood pressure in patients with type 2 diabetes: an analysis of data from electronic medical records. *Clin Ther*, 33(1), 110-20.
16. LaFleur J, **McAdam-Marx C**, Alder SS, Sheng X, Asche CV, Nebeker J, Brixner DI, Silverman SL (2011). Clinical risk factors for fracture among postmenopausal patients at risk for fracture: a historical cohort study using electronic medical record data. *J Bone Miner Metab*, 29(2), 193-200.
17. Nelson RE, **McAdam-Marx C**, Evans ML, Ward R, Campbell B, Brixner D, Lafleur J (2011). Patent extension policy for paediatric indications: an evaluation of the impact within three drug classes in a state Medicaid programme. *Appl Health Econ Health Policy*, 9(3), 171-81.
18. **McAdam-Marx C**, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI (2011). All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. *J Manag Care Pharm*, 17(7), 531-46.
19. **McAdam-Marx C**, Unni S, Ye X, Nelson S, Nickman NA (2012). Effect of Medicare reimbursement reduction for imaging services on osteoporosis screening rates. *J Am Geriatr Soc*, 60(3), 511-6.
20. LaFleur J, **McAdam-Marx C**, White GL, Lyon JL, Oderda GM (2012). Comparing Medication Adherence Methods in Lipid-Modifying Therapy. *J Pharm Technol*, 28(2), 58-67.
21. Jennings BT, Marx CM (2012). Implementation of a pharmacist-managed diabetes program. *Am J Health Syst Pharm*, 69(22), 1951-3.
22. Kirkness CS, **McAdam-Marx C**, Unni S, Young J, Ye X, Chandran A, Peters CL, Asche CV (2012). Characterization of patients undergoing total knee arthroplasty in a real-world setting and pain-related medication prescriptions for management of postoperative pain. *J Pain Palliat Care Pharmacother*, 26(4), 326-33.

23. Kirkness CS, **McAdam-Marx C**, Unni S, Young J, Ye X, Chandran A, Peters CL, Asche CV (2013). Characterization of patients undergoing total hip arthroplasty in a real-world setting and pain-related medication prescriptions for management of postoperative pain. *J Pain Palliat Care Pharmacother*, 27(3), 235-43.
24. Robinson M, Gunning K, Pippitt K, **McAdam-Marx C**, Jennings BT (2013). Team-based approach to addressing simvastatin safety concerns. *J Am Pharm Assoc (2003)*, 53(5), 539-44.
25. Cai B, **McAdam-Marx, C** (2014). The Determinants of antihypertensive use and expenditure inpatients with hypertension in the United States. *J Pharm Health Serv Res*, 5(1), 11-18.
26. **McAdam-Marx C**, Mukherjee J, Bellows BK, Unni S, Ye X, Iloeje U, Brixner DI (2014). Evaluation of the relationship between weight change and glycemic control after initiation of antidiabetic therapy in patients with type 2 diabetes using electronic medical record data. *Diabetes Res Clin Pract*, 103(3), 402-11.
27. **McAdam-Marx C**, Bellows BK, Unni S, Wygant G, Mukherjee J, Ye X, Brixner DI (2014). Impact of adherence and weight loss on glycemic control in patients with type 2 diabetes: cohort analyses of integrated medical record, pharmacy claims, and patient-reported data. *Journal of Managed Care & Specialty Pharmacy*, 20(7), 691-700.
28. Buu J, Mullin S, **McAdam-Marx C**, Solomon M, and Jennings BT (2014). Identifying Barriers to Influenza Vaccination Recommendation Adherence in an Academic Outpatient Primary Care Clinic Setting. *Innovations in Pharmacy*, 5(3), Article 4.
29. Shane-McWhorter L, Lenert L, Petersen M, Woolsey S, **McAdam-Marx C**, Coursey JM, Whittaker TC, Hyer C, LaMarche D, Carroll P, Chuy L (2014). The Utah Remote Monitoring Project: improving health care one patient at a time. *Diabetes Technol Ther*, 16(10), 653-60.
30. **McAdam-Marx C**, Bellows BK, Unni S, Mukherjee J, Wygant G, Iloeje U, Liberman JN, Ye X, Bloom FJ, Brixner DI (2014). Determinants of glycaemic control in a practice setting: the role of weight loss and treatment adherence (The DELTA Study). *Int J Clin Pract*, 68(11), 1309-17.
31. **McAdam-Marx C**, Dahal A, Jennings B, Singhal M, Gunning K (2015). The effect of a diabetes collaborative care management program on clinical and economic outcomes in patients with type 2 diabetes. *Journal of Managed Care & Specialty Pharmacy*, 21(6), 452-68.
32. Dahal A, **McAdam-Marx C**, Smith B, Shane-McWhorter L (2015). Improving Diabetes Care in Underserved Patients through a "Learning Your ABCs" Education and Screening Program. *Pharmaceutical Care & Health Systems*. *Journal of Pharmaceutical Care & Health Systems*, 2(3), 140.
33. Jacquez M, Moorman K, **McAdam-Marx C**, Owen D, Schauerhamer MB, Jennings BT (2016). Identification of medication related problems during medication reviews in a community setting. *Journal of Clinical and Hospital Pharmacy*, 2015; 1(2), 9-13.
34. Shane-McWhorter L, **McAdam-Marx C**, Lenert L, Petersen M, Woolsey S, Coursey JM, Whittaker TC, Hyer C, LaMarche D, Carroll P, Chuy L (2015). Pharmacist-provided diabetes management and education via a telemonitoring program. *J Am Pharm Assoc (2003)*, 55(5), 516-26.

35. Kawamoto K, Anstrom KJ, Anderson JB, Bosworth HB, Lobach DF, **McAdam-Marx C**, Ferranti JM, Shang H, Yarnall KS (2016). Long-Term Impact of an Electronic Health Record-Enabled, Team-Based, and Scalable Population Health Strategy Based on the Chronic Care Model. *AMIA Annu Symp Proc*, 2016, 686-695.
36. Shane-McWhorter L, **McAdam-Marx C**, Lenert L, Petersen M, Woolsey S, Coursey JM, Whittaker TC, Hyer C, LaMarche D, Carroll P, Chuy L (2016). Augmenting Telemonitoring Interventions by Targeting Patient Needs in a Primarily Hispanic Underserved Population. *Diabetes Spectr*, 29(2), 121-7.
37. **McAdam-Marx C**, Nguyen H, Schauerhamer MB, Singhal M, Unni S, Ye X, Cobden D (2016). Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis. *Clin Ther*, 38(12), 2642-2651.
38. Humphries MD, Suckow BD, Binks JT, **McAdam-Marx C**, Kraiss LW (2017). Elective Endovascular Aortic Aneurysm Repair Continues to Cost More than Open Abdominal Aortic Aneurysm Repair. *Ann Vasc Surg*, 39, 111-118.
39. Singhal M, Unni S, Schauerhamer M, Nguyen H, Hurd J, **McAdam-Marx C** (2017). Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes. *J Manag Care Spec Pharm*, 23(3), 267-275.
40. Biltaji E, Yoo M, Jennings B, Leiser J, **McAdam-Marx C** (2017). Outcomes Associated with Pharmacist-Led Diabetes Collaborative Drug Therapy Management in a Medicaid Population. *J Pharm Health Serv Res*. Mar;8(1):59-62.

B. Review Articles

1. Asche CV, Kirkness CS, **McAdam-Marx C**, Fritz JM (2007). The societal costs of low back pain: data published between 2001 and 2007. [Review]. *J Pain Palliat Care Pharmacother*, 21(4), 25-33.
2. LaFleur J, Said Q, **McAdam-Marx C**, Jackson K, Mortazavi M (2007). Problems in studying the association between race and pain in outcomes research. [Review]. *J Pain Palliat Care Pharmacother*, 21(3), 57-62.
3. **McAdam-Marx C**, LaFleur, J, Kirkness C, Asche C (2007). Postmenopausal osteoporosis: Current and future treatment options. [Review]. *PT*, 32(7), 392-402.
4. LaFleur J, **McAdam-Marx C**, Kirkness C, Brixner DI (2008). Clinical risk factors for fracture in postmenopausal osteoporotic women: a review of the recent literature. [Review]. *Ann Pharmacother*, 42(3), 375-86.
5. **McAdam-Marx C**, Schaaf DT, Holtorf AP, Eng B, Oderda GM (2008). Systematic analysis of outcomes evaluations applied to drug management programs. [Review]. *Am J Manag Care*, 14(11 Suppl), SP36-45.
6. Brixner DI, **McAdam-Marx C** (2008). Cost-effectiveness of insulin analogs. [Review]. *Am J Manag Care*, 14(11), 766-75.
7. Holtorf AP, **McAdam-Marx C**, Schaaf D, Eng B, Oderda G (2009). Systematic review on quality control for drug management programs: is quality reported in the literature? [Review]. *BMC Health Serv Res*, 9, 38.
8. Young JR, **McAdam-Marx C** (2010). Treatment of type 1 and type 2 diabetes mellitus with insulin detemir, a long-acting insulin analog. [Review]. *Clin Med*

Insights Endocrinol Diabetes, 3, 65-80.

9. **McAdam-Marx C**, Gaebler JA, Bellows BK, Brixner DI (2010). Contemporary management of patients with Type 2 diabetes. [Review]. *Expert Rev Cardiovasc Ther*, 8(6), 767-70.
10. Ghate SR, Haroutiunian S, Winslow R, **McAdam-Marx C** (2010). Cost and comorbidities associated with opioid abuse in managed care and Medicaid patients in the United States: a comparison of two recently published studies. [Review]. *J Pain Palliat Care Pharmacother*, 24(3), 251-8.
11. Munger MA, Shane-McWhorter L, **McAdam-Marx C** (2010). Prediabetes: Implications for Managed Care. *Am J Pharm Benefits*. 2010;2(7):429-441. [Review]. *American Journal of Pharmacy Benefits*, 2(7), 429-441.
12. Bellows BK, Hunter E, **McAdam-Marx C** (2011). Exenatide: Review of its Role as Adjunctive Therapy in Patients with Type 2 Diabetes. [Review]. *Clin Med Rev Vasc Health*, 2011(3).
13. Lin J, Jiao T, Biskupiak JE, **McAdam-Marx C** (2013). Application of electronic medical record data for health outcomes research: a review of recent literature. [Review]. *Expert Rev Pharmacoecon Outcomes Res*, 13(2), 191-200.
14. **McAdam Marx C** (2013). Economic implications of type 2 diabetes management. [Review]. *Am J Manag Care*, 19(8 Suppl), S143-8.
15. Bellows BK, Kuo KL, Biltaji E, Singhal M, Jiao T, Cheng Y, **McAdam-Marx C** (2014). Real-world evidence in pain research: a review of data sources. [Review]. *J Pain Palliat Care Pharmacother*, 28(3), 294-304.
16. Schauerhamer MB, Gurgle H, **McAdam-Marx C** (2015). Once-weekly exenatide as a treatment for Type 2 diabetes. [Review]. *Expert Rev Cardiovasc Ther*, 13(6), 611-26.
17. Gurgle HE, White K, **McAdam-Marx C** (2016). SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives. [Review]. *Vasc Health Risk Manag*, 12, 239-49.

C. Abstracts

1. **McAdam-Marx C**, Joish VN, Brixner DI, Arondekar B, Hoblyuk R (2006). *A comparison of adherence and cost of sulfonylureas in combination with TZDs or metformin. The American Diabetes Association 66th Annual Scientific Session* [Abstract]. *Diabetes*, 55(1).
2. Asche CV, **McAdam-Marx C**, Shane-McWhorter L, Sheng X, Plauschinat CA (2007). *Association between oral antidiabetic adverse events and outcomes in a real-world setting. American Diabetes Association 67th Annual Scientific Meeting* [Abstract]. *Diabetes*, 56(1).
3. **McAdam-Marx C**, Brixner DI, Metraux S, Moelter S, Field R (2009). *Antidiabetic Treatment and A1C Testing in Youth with Type 2 Diabetes in an Ambulatory Care Setting. The American Diabetes Association 69th Annual Scientific Session* [Abstract]. *Diabetes*, 58(1).
4. Brixner D, **McAdam-Marx C**, Nelson R, Aagren M, Bouchard J (2009). *Analysis of glycemic control and weight changes in patients treated with analog basal insulin in a real-world setting. The American Diabetes Association 69th Annual Scientific Session* [Abstract]. *Diabetes*, 58(1).
5. **McAdam-Marx C**, Brixner DI, Ye X, Misurski D, Fabunmi R (2009). *A1C*

Outcomes at 6 and 18 Months in Insulin Naïve Patients with Type 2 Diabetes Treated with Analog Basal Insulin in an Ambulatory Care Setting. The American Diabetes Association 69th Annual Scientific Session [Abstract]. Diabetes, 58(1).

D. Poster Presentations

1. Brixner DI, Joish VM, **McAdam-Marx C**, Arondekar B, Hoblyuk R (2006). *Evaluation of persistence and outcomes in patients on SU combination therapy with TZDs or Metformin.* Poster session presented at AMCP 18th Annual Meeting, Seattle, WA.
2. Asche CV, **McAdam-Marx C**, Share-McWhorter L, Plauschinat CA (2006). *Evaluation of diabetes treatment patterns and adverse events in a usual care setting.* Poster session presented at American Society of Health-System Pharmacists 41st Mid-Year Meeting, Anaheim, CA.
3. LaFleur J, Asche C, **McAdam-Marx C**, Alder S, Sheng X (2006). *Postmenopausal osteoporosis fracture occurrence and fracture rates by age in a primary-care setting.* Poster session presented at American Society of Health-System Pharmacists 41st Mid-Year Meeting, Anaheim, CA.
4. Brixner D, Asche CV, **McAdam-Marx C**, Gallwitz W (2006). *Value of reducing vertebral fractures in women with post-menopausal osteoporosis with multiple clinical risk factors for fracture based on the TOPS study.* Poster session presented at American Society of Health-System Pharmacists 41st Mid-Year Meeting, Anaheim, CA.
5. LaFleur J, Asche C, **McAdam-Marx C**, Alder S, Sheng X (2007). *Postmenopausal osteoporosis fracture occurrence and fracture rates by age in a primary-care setting.* Poster session presented at 3rd Annual Utah Health Services Research Conference, Salt Lake City, UT.
6. **McAdam-Marx C**, Brixner D, Metrau S, Chan V, Field R (2007). *Determinants of race and ethnicity reporting for youth with health data in an electronic medical record database.* Poster session presented at University of the Sciences Scholarly Day, Philadelphia, PA.
7. LaFleur J, **McAdam-Marx C**, Asche CV, Alder S, Sheng X, Brixner D, Silverman S (2007). *The risk of clinical vertebral fracture for postmenopausal patients with specific combinations of fracture risk factors in a primary-care setting.* Poster session presented at National Osteoporosis Foundation, 7th International Symposium on Osteoporosis: Translating Research into Clinical Practice., Washington, DC.
8. LaFleur J, **McAdam-Marx C**, Asche CV, Alder S, Sheng X, Brixner D, Silverman S (2007). *Clinical risk factors for fracture are additive in postmenopausal women who are at risk for fracture in a primary care setting.* Poster session presented at The American Society of Bone and Mineral Research 29th Annual Meeting, Honolulu, HI.
9. Asche CV, Seal B, **McAdam-Marx C**, Crookston B, Svejda R, Mullins CD (2007). *Treatment costs associated with community acquired pneumonia by community level antimicrobial resistance.* Poster session presented at ISPOR 10th Annual European Congress, Dublin, Ireland.
10. **McAdam-Marx C**, Brixner DI, Asche C (2008). *Identifying potential adverse events in an electronic medical record database.* Poster session presented at 4th Annual Utah Health Services Research Conference, Salt Lake City, UT.

11. Brixner DI, **McAdam-Marx C**, Biskupiak J, Lau HJ, Munger M (2008). *Association of adverse events of antihypertensive therapy by age in a physician practice national EMR database*. Poster session presented at American Heart Association 9th Scientific Quality of Care in Cardiovascular Disease and Stroke, Baltimore, MD.
12. **McAdam-Marx C**, Brixner DI, Ye X, Sung JC, Kahler KH (2008). *Evaluation of resistant hypertension in a usual-care setting*. Poster session presented at 13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Toronto, Canada.
13. Nelson R, **McAdam-Marx C**, Misurski DA, Nielsen LL (2008). *Descriptive analysis of body weight and clinical effectiveness measures associated with type 2 diabetes therapies in a primary care electronic medical record database*. Poster session presented at 13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Toronto, Canada.
14. **McAdam-Marx C**, Brixner DI, Oberg B (2008). *Estimation of study population size for effectiveness outcomes at 6 and 12 months via electronic medical records*. Poster session presented at 13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Toronto, Canada.
15. **McAdam-Marx C**, Brixner DI, Field R, Metraux S (2008). *Type 2 diabetes in youth: 2002 and 2006 prevalence and obesity in a primary care setting*. Poster session presented at 13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Toronto, Canada.
16. Lafleur J, Nelson R, **McAdam-Marx C**, Brixner D, Ward R (2008). *Patent extension policies for pediatric indications: an evaluation of the impact within one drug class in one state Medicaid program*. Poster session presented at Academy Health 2008 Annual Meeting, Washington, DC.
17. Brixner DI, **McAdam-Marx C**, Ye X, Misurski D, Wintle M, Fabunmi R (2009). *18 month A1C and Weight Outcomes of Exenatide Therapy in Patients with Type 2 Diabetes in a Real-World Study*. Poster session presented at 14th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Orlando, FL.
18. **McAdam-Marx C**, Brixner DI, Ye X, Misurski D, Fabunmi R (2009). *A1C and Weight Outcomes Following 6 Months of Analog Basal Insulin in Insulin Naïve Patients with Type 2 Diabetes in an Ambulatory Care Setting*. Poster session presented at 14th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Orlando, FL.
19. **McAdam-Marx C**, Yu Y, Shankar V, Bouchard J, Brixner D (2009). *Daily Average Consumption of Basal Insulin in Patients with Type 2 Diabetes*. Poster session presented at 14th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Orlando, FL.
20. Fabunmi R, **McAdam-Marx C**, Ye X, Misurski D, Brixner D (2009). *Blood Pressure Outcomes after 6 Months of Exenatide Treatment in Patients with Type 2 Diabetes in a Real World Study*. Poster session presented at The American Diabetes Association 69th Annual Scientific Meeting, New Orleans, LA.
21. **McAdam-Marx C**, Nelson R, Aagren M, Bouchard J, Brixner DI (2009). *Analysis of glycaemic control outcomes vs. baseline in patients treated with analog basal insulin in a real-world setting*. Poster session presented at International Diabetes Federation 20th World Diabetes Congress, Montreal, Canada.

22. Brixner DI, **McAdam-Marx C**, Van Den Bos J, Perlman D (2010). *Resource Use for Caregivers vs. Matched Controls One-Year Pre vs. Post Patient Diagnosis for Alzheimer Disease*. Poster session presented at American Geriatrics Society Annual Scientific Meeting, Orlando, FL.
23. Brixner DI, **McAdam-Marx C**, Van Den Bos J, Perlman D (2010). *Costs One Year Post Diagnosis for Alzheimer Patients and their Spouses vs. Matched Controls*. Poster session presented at 2010 American Geriatrics Society Annual Scientific Meeting, Orlando, FL.
24. Brixner DI, **McAdam-Marx C**, Van Den Bos J, Perlman D (2010). *Approach to Matching Patients with Alzheimer's Disease and their Spouse to Control Patients in Spouses in an Administrative Claims Database*. Poster session presented at 15th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Atlanta, GA.
25. Pepper MJ, Shane-McWhorter, Bellows B, **McAdam-Marx C**, Albright F, Osborne B (2010). *Exercise in Hispanic patients with type 2 diabetes mellitus: can a Spanish exercise DVD help*. Poster session presented at American Association of Diabetes Educators Annual Conference, San Antonio, TX.
26. **McAdam-Marx C**, Unni S, Nelson S, Ye X, Nickman N (2011). *An evaluation of bone mineral density screening and technology frequency (2005-2008) among US women age 50 and older in a commercial medical claims database*. Poster session presented at 17th Annual Meeting of the International Society of Clinical Densitometry, Miami, FL.
27. **McAdam-Marx C**, Hane C, Biskupiak J, Deniz B, McGarry LI, Brixner DI (2011). *Costs Associated with HCV and Related Complications in the United States from a Managed Care Payer's Perspective*. Poster session presented at 15th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Baltimore, MD.
28. **McAdam-Marx C**, Bouchard J, Aagren M2, Conner C, Brixner D (2011). *Baseline Characteristics and Antidiabetic Exposure in Patients with Type 2 Diabetes Treated with Liraglutide*. Poster session presented at 15th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Baltimore, MD.
29. **McAdam-Marx C**, Ye X, Bouchard J, Aagren M, Conner C, Brixner D (2011). *Bootstrapping used to provide robust mean and variance estimates for comparing patients treated with liraglutide to a large comparison cohort*. Poster session presented at 15th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Baltimore, MD.
30. **McAdam-Marx C**, Jennings B, Sayler M, Gunning K (2011). *An Evaluation of Clinical and Economic Outcomes Associated with a Pharmacist-Coordinated Diabetes Chronic Care Management Program*. Poster session presented at American Association of Colleges of Pharmacy Annual Meeting, San Antonio, TX.
31. **McAdam-Marx C**, Brixner D, Ye X, Unni S, Mukherjee J (2011). *Weight Loss, Independent of Drug Class, Predicts HbA1c Goal Attainment in Patients 65 years and Older in a Real-World Setting*. Poster session presented at International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Madrid, Spain.
32. Mukherjee J, **McAdam-Marx C**, Ye X, Unni S, Brixner D (2011). *Weight loss of 3% or more of baseline body weight in a 12-month period is associated with glycemic*

control in newly treated type 2 diabetes patients in the usual care setting. Poster session presented at 47th European Association for the Study of Diabetes Annual Meeting, Lisbon, Spain.

33. Robinson MM, Gunning K, Pippitt K, **McAdam-Marx C**, Jennings B (2012). *Bridging the Gap Between FDA Safety Warnings and Patients: Are Pharmacists the Appropriate Messengers.* Poster session presented at APhA Annual Meeting, New Orleans, LA.
34. Bellows BK, **McAdam-Marx C**, Unni S, Ye X, Mukherjee J, Brixner DI (2012). *12-month HbA1c and Weight Outcomes by Drug Class in Treatment Naïve Patients with Type 2 Diabetes.* Poster session presented at Academy of Managed Care Pharmacy Annual Meeting, San Francisco, CA.
35. Cai B, **McAdam-Marx C** (2012). *Using Longitudinal Data to Explain the Impact of Pain on Depression for the General Population.* Poster session presented at International Society of Pharmacoeconomics and Outcomes Research (ISPOR) International Meeting, Washington DC.
36. Cai B, **McAdam-Marx C** (2012). *Determinants of Pharmaceutical Expenditures for Patients with Hypertension.* Poster session presented at International Society of Pharmacoeconomics and Outcomes Research International Meeting, Washington DC.
37. Bellows BK, Ye X, Unni S, Mukherjee J, Iloeje U, **McAdam-Marx C** (2012). *Impact of Anti-diabetic Drug Selection on Weight Change and HbA1c Outcomes in Treatment Naïve Patients with Type 2 Diabetes.* Poster session presented at American Diabetes Association Scientific Sessions, Philadelphia PA.
38. **McAdam-Marx C**, Jennings BT, Dahal A, Gunning K (2012). *Pharmacist-led diabetes chronic care management program improves glycemic control without increasing costs in patients with uncontrolled type 2 diabetes.* Poster session presented at American College of Clinical Pharmacy Annual Meeting, Hollywood, FL.
39. **McAdam-Marx C**, Jennings BT, Dahal A, Gunning K (2012). *Pharmacist-led diabetes collaborative drug therapy management program improves glycemic control in patients with uncontrolled type 2 diabetes treated with insulin.* Poster session presented at American College of Clinical Pharmacy Annual Meeting, Hollywood, FL.
40. **McAdam-Marx C**, Bellows B, Wygant G, Mukherjee J, Unni S, Ye X, Iloeje U, Brixner D (2012). *Weight loss of $\geq 3\%$ of body weight after initiating new anti-diabetic therapy is associated with glycemic control at 6 months in patients with type 2 diabetes.* Poster session presented at International Society of Pharmacoeconomics and Outcomes Research (ISPOR) European Meeting, Berlin, Germany.
41. **McAdam-Marx C**, Bellows B, Wygant G, Mukherjee J, Unni S, Ye X, Liberman J, Iloeje U, Brixner D (2012). *Association of a $\geq 3\%$ loss of body weight and self-reported adherence with glycemic control at 6 months after initiating new anti-diabetic therapy in patients with type 2 diabetes (T2DM) – the DELTA Study.* Poster session presented at The Conference on Diabetes and Hypertension Europe (CODHy EU), Barcelona, Spain.
42. Hays E, Gunning K, **McAdam-Marx C**, Pippitt K (2013). *Pharmacist Intervention to Decrease Risk of Hypoglycemia in Older Patients with Diabetes Mellitus.* Poster

session at Society of Teachers of Family Medicine Conference, Baltimore, MD.

43. **McAdam-Marx C**, Bellows B, Wygant G, Mukherjee J, Unni S, Ye X, Liberman J, Iloeje U, Brixner D (2013). *Association of $\geq 5\%$ weight loss and self-reported adherence with 6-month glycemic control in type 2 diabetes mellitus (T2DM): the DELTA Study*. Poster session presented at American Diabetes Association Scientific Sessions, Chicago, IL.
44. Humphries MD, Suckow BD, Binks JT, **McAdam-Marx C**, Kraiss LW (2013). *EVAR Continues to Cost More than Open AAA Repair*. Poster session presented at Western Vascular Society Annual Meeting, Alberta, Canada.
45. Turner K, Gurgle H, Hardcastle A, **McAdam-Marx C** (2013). *Assessment of student pharmacist experience at an interprofessional student-run free clinic*. Poster session presented at American College of Clinical Pharmacy Annual Meeting, Albuquerque NM.
46. Spence B, **McAdam-Marx C**, Mullins S, Choudhary K (2013). *Association Between Clinically Aligned Pain Assessment and Opioid Use Compared to a Numeric Rating Scale Pain Assessment in Hospitalized Patients*. Poster session presented at American Society of Hospital Pharmacist Mid-Year Meeting, Orlando, FL.
47. Wong R, **McAdam-Marx C**, Bellows B (2013). *Cost-effectiveness of lorcaserin in treating overweight or obese patients with type 2 diabetes*. Poster session presented at American Society of Hospital Pharmacist Mid-Year Meeting, Orlando, FL.
48. Winter B, Turner K, **McAdam-Marx C**, Biltaji E, Gunning K (2013). *Survey of smoking cessation practices among pharmacists*. Poster session presented at American Society of Hospital Pharmacist Mid-Year Meeting, Orlando, FL.
49. Buu J, Mullin S, **McAdam-Marx C**, Solomon M, Jennings BT (2014). *Developing a Process to Improve Adult Influenza Vaccination Rates and Guideline Implementation in a Clinic Setting*. Poster session presented at American Pharmacists Association (APhA) Annual Meeting & Exposition, Los Angeles, CA.
50. Jacquez M, Moorman K, **McAdam-Marx C**, Owen D, Jennings B (2014). *The identification of medication related problems from a medication review provided by a clinical pharmacist in a community setting*. Poster session presented at American Pharmacists Association (APhA) Annual Meeting & Exposition, Orlando, FL.
51. Shane-McWhorter L, **McAdam-Marx C**, Deka R (2014). *Pharmacist-Provided Diabetes Education and Care Via Telemonitoring: The Utah Remote Monitoring Project*. Poster session presented at 9th Annual Utah Health Services Research Conference, Salt Lake City, UT.
52. Ogborn DB, Gunning K, Gibson KL, **McAdam-Marx C**, Lowe M, Jennings BT (2014). *Immunization Rates in Pregnant Women through Quality-Improvement Changes in Electronic Medical Record Processes*. Poster session presented at American Pharmacists Association (APhA) Annual Meeting & Exposition, Los Angeles, CA.
53. **McAdam-Marx C**, Bellows B, Wygant G, Mukherjee J, Unni S, Ye X, Iloeje U, Brixner D (2013). *Associations between claims based adherence, weight loss and glycemic control in patients with type 2 diabetes*. Poster session presented at International Society of Pharmacoeconomics and Outcomes Research (ISPOR) International Meeting, New Orleans, LA.
54. **McAdam-Marx C**, Biltaji E, Yoo M, PhD, Jennings BT, Gunning K (2014). *Clinical and Economic Impact of a Pharmacist-Led Diabetes Collaborative Drug*

Therapy Management Program in a Medicaid ACO Setting. Poster session presented at Academy of Managed Care Pharmacy, Boston, MA.

55. Gurgle H, **McAdam-Marx C**, Singhal M, Wier P (2014). *Clinical and economic outcomes of a collaborative diabetes management program in an employer-sponsored family medicine clinic.* Poster session presented at ACCP Annual Meeting, San Antonio, Tx.
56. Gurgle H, **McAdam-Marx C**, Singhal M, Weir P (2014). *Evaluation of diabetes outcomes after implementation of clinical pharmacist services in an employer-sponsored family medicine clinic.* Poster session presented at ACCP Annual Meeting, San Antonio, Tx.
57. Unni S, Nguyen N, Schauerhamer M, Ye X, Cobden D, **McAdam-Marx C** (2015). *Achievement of Glycemic Control and Antidiabetic Therapy Changes in Type 2 Diabetes Patients Initiating Glucagon-like Peptide-1 Receptor Agonist Therapy.* Poster session presented at Academy of Managed Care Pharmacy Annual Meeting, San Diego, CA.
58. Rodriques S, Gurgle H, **McAdam-Marx C** (04/07/2015). *Cost Impact of Adopting ACC/AHA Cholesterol Guidelines in an Employer Based Primary Care Clinic.* Poster session presented at AMCP Annual Meeting, San Diego, CA.
59. Singhal M, Nguyen H, Schauerhamer M, Unni S, Cobden D, **McAdam-Marx C** (2015). *Effect of Daily or Weekly GLP-1 Receptor Agonists on Glycemic Control in Insulin-Naïve Patients with Poorly Controlled Type 2 Diabetes: A Real-World Study.* Poster session presented at International Society for Pharmacoeconomic and Outcomes Research (ISPOR) Annual Meeting, Philadelphia, PA.
60. Singhal M, **McAdam-Marx C**, LaFleur J, Witt DM, Nelson R, Biskupiak JE (2015). *Role of glycemic control in development of Atrial Fibrillation in patients with Type 2 diabetes mellitus.* Poster session presented at International Society for Pharmacoeconomic and Outcomes Research (ISPOR) Annual Meeting, Washington, DC.
61. **McAdam-Marx C**, Nguyen H, Schauerhamer M, Ye X, Singhal M, Cobde D (2015). *Real-World 1-Year HbA1c and Weight Outcomes in Patients Treated with Exenatide Once Weekly or Liraglutide Once Daily.* Poster session presented at American Diabetes Association Scientific Sessions, Boston, MA.
62. Biltaji E, Brixner D, **McAdam-Marx C**, Schiffman J, Sweeney C, Gligorich K, Bronner M, Stenehjem D (2015). *Characterization of NGS testing at Huntsman Cancer Institute.* Poster session presented at Translating Cancer Epidemiology: from Cells to Clinic and Population Conference, Salt Lake City, UT.
63. Tak C, Unni S, Gunning K, **McAdam-Marx C** (2016). *2014 Pneumococcal Immunization Rates by Race and Ethnicity.* Poster session presented at 11th Annual Utah Health Services Research Conference, Salt Lake City, UT.
64. Fortenberry K, Willis SK, Schauerhamer M, **McAdam-Marx C**, Gren L (2016). *Achieving Glycemic Control in Patients with Type 2 Diabetes Mellitus and Mental Health Conditions.* Poster session presented at APHA Annual Meeting & Expo, Denver, CO.
65. Kawamoto K, Anstrom KJ, Anderson JB, Bosworth HB, Lobach DF, **McAdam-Marx C**, Ferranti JM, Shang H, Hawblitzel Yarnall KS (2016). *Long-Term Impact of an Electronic Health Record-Enabled, Team-Based, and Scalable Population Health Strategy Based on the Chronic Care Model.* AMIA Symposium

2016, Chicago, IL.

66. Singhal M, Schauerhamer MB, Wittbrodt E, Unni S, Hurd J, **McAdam-Marx C** (2017). *Achievement of Diabetes-Related Quality Measures in Patients Treated with Exenatide Once-Weekly in a Real-World Setting*. Poster session presented at International Society for Pharmacoeconomic and Outcomes Research 22nd Annual International Meeting, Boston, MA.
67. Unni S, Schauerhamer MB, Ma J, Wittbrodt E, Hurd J, Ye X, **McAdam-Marx C** (2017). *Real-World Glycemic Control after 6 Months of Treatment with Exenatide Once Weekly vs. Dulaglutide or Albiglutide in Patients with Type 2 Diabetes*. Poster session presented at American Diabetes Association 77th Scientific Sessions, San Diego, CA.
68. Ruiz-Negrón N, Wittbrodt E, Ma J, Unni S, Hurd J, **McAdam-Marx C** (2017). *Real-World A1C and Weight Outcomes with Long-Acting GLP-1 Receptor Agonist Treatment by Insulin Use In Patients with Poorly Controlled Type 2 Diabetes*. Poster session presented at American Diabetes Association 77th Annual Scientific Sessions, San Diego, CA.

E. Other (Commentary/Letters/Editorials/Case Reports/Video/Film)

A. Commentary

1. **McAdam-Marx C** (2012). Commentary: Managed Care Pharmacy Perspective in Evaluating Current Modes for Insulin Delivery and Glucose Monitoring in Patients with Diabetes. *J Manag Care Pharm*, 18(6), S14.

B. Letters

1. **McAdam-Marx C**, Ye X, Brixner DI, Fabunmi R, Wintle M, Boye KS, Misurski D, Nielsen LL (2009). A1C and weight outcomes at 18 months in patients with type 2 diabetes treated with exenatide in an ambulatory care setting [Letter to the editor]. *Diabetes, Obesity and Metabolism Online*, 11(12), 1173-4.

C. Video/Film/CD/Web/Podcast

1. **McAdam-Marx C** (08/15/2015). The Scope Radio: There a Pharmacist in the House? [Podcast]. Salt Lake City, UT: University of Utah Health Sciences Radio. Available: http://healthcare.utah.edu/the-scope/shows.php?shows=0_q3mn2x02.

F. Pending Publications

A. Journal Articles

1. Brown K, Fortenberry K, Gren L, Gunning K, **McAdam-Marx C** (In Press). Achievement of Adequate Glycemic Control in Patients with Type 2 Diabetes and Comorbid Mental Health Conditions Treated in a Primary Care Setting. *Diabetes Spectrum*.
2. Geurts K, Berrett GB, **McAdam-Marx C**, Schauerhamer MB, Deshmukh VG, McKennon S (Submitted). Evaluation of Statin Use for Primary Prevention in Patients with Type 2 Diabetes Mellitus: A Retrospective Study. *Am J Manag Care*.

B. Review Articles

1. Schauerhamer M, **McAdam-Marx C** (In Press). The clinical and economic consequences of medication non-adherence in patients with diabetes. *Medicographia*.

V. FUNDING

A. Active Grants

- 12/04/14 - 12/31/17 Improving Pneumococcal Immunization Rates and Series Adherence in the Elderly and High-Risk Adults
Principal Investigator: Carrie McAdam-Marx
Direct Costs: \$308,216 Total Costs: \$409,002
Merck & Company, Inc.
Role: Principal Investigator
- 12/16/14 - 09/30/17 Glycemic Control and Weight-Loss with Bydureon versus Liraglutide and Dulaglutide
Principal Investigator: Carrie McAdam-Marx
Direct Costs: \$130,708 Total Costs: \$173,450
ASTRA-ZENECA
Role: Principal Investigator
- 08/01/16 - 07/31/17 Qualitative Research into the Barriers for Effective Patient Self-Management of Comorbid Diabetes, Obesity, and Asthma
Principal Investigator: Michael Feehan
Direct Costs: \$24,960 Total Costs: \$24,960
Community Pharmacy Foundation
Role: Co-Investigator
- 09/01/16 - 08/31/18 Factors Associated with and the Impact of Treatment Inertia on Attainment of HbA1c Quality Measures in a Managed Care
Principal Investigator: Brandon K. Bellows
Direct Costs: \$399,504 Total Costs: \$479,112
Janssen Pharmaceuticals, Inc.
Role: Co-Investigator
- 12/15/16 - 11/07/17 T2DM Treatment Intensification
Principal Investigator(s): Diana I. Brixner, Carrie McAdam-Marx
Direct Costs: \$187,015 Total Costs: \$246,150
Sanofi-Aventis
Role: Co-Principal Investigator

B. Pending Grants

C. Past Grants/Contracts

- 11/20/07 - 06/30/10 Evaluation of Resistant Hypertension
Principal Investigator(s): Diana I. Brixner; Carrie McAdam-Marx
Direct Costs: \$36,546 Total Costs: \$48,496
Novartis Pharmaceuticals Corp
Role: Co-Principal Investigator
- 12/21/07 - 03/31/08 Real-World Prevalence of Resistant Hypertension
Principal Investigator: Carrie McAdam-Marx

Direct Costs: \$7,536 Total Costs: \$10,000
 Novartis Pharmaceuticals Corporation
 Role: Principal Investigator
 09/01/08 - 02/09/09 Profile of Patients with Hypertension Initiated on Aliskerin:
 Identification of Patient Characteristics and Prior Treatment
 Trends
 Principal Investigator: Carrie McAdam-Marx
 Direct Costs: \$90,580 Total Costs: \$120,200
 Novartis Pharmaceuticals Corporation
 Role: Principal Investigator
 10/26/09 - 12/31/09 Risk of Thrombotic Events in Clopidogel Patients Treated with a
 Proton Pump Inhibitor versus Carafate
 Principal Investigator(s): Diana I. Brixner; Michael Goodman;
 Carrie McAdam-Marx
 Direct Costs: \$23,500 Total Costs: \$31,185
 Axcan Pharma, Inc.
 Role: Co-Principal Investigator
 10/15/10 - 10/14/11 Frequency of Bone Mineral Density Testing Among Women with
 Osteoporosis
 Principal Investigator: Nancy A. Nickman
 Direct Costs: \$35,500 Total Costs: \$47,109
 Novartis Pharmaceuticals Corporation
 Role: Co-Investigator
 11/01/10 - 06/30/11 Glycemia, Weight, and Blood Pressure Outcomes after 3 Months
 of Liraglutide Treatment in Patients with Type 2 Diabetes in a
 Real-World Setting
 Principal Investigator(s): Diana I. Brixner; Carrie McAdam-Marx
 Direct Costs: \$88,760 Total Costs: \$117,785
 Novo Nordisk Pharmaceuticals, Inc.
 Role: Co-Principal Investigator
 01/01/11 - 12/31/11 Clinical and Economic Outcomes Associated with Community-
 Based, Intensive Insulin Management in Patients with Type 2
 Diabetes
 Principal Investigator: Carrie McAdam-Marx
 Direct Costs: \$60,000 Total Costs: \$60,000
 PhRMA Foundation
 Role: Principal Investigator
 01/15/11 - 01/14/12 Patient and Medical Practice Outcomes Associated with a
 Pharmacist Coordinated Diabetes Chronic Care Management
 Program: Pilot Data to Support a Program Expansion
 Demonstration Project
 Principal Investigator: Carrie McAdam-Marx
 Direct Costs: \$9,898 Total Costs: \$9,898
 American Association of Colleges of Pharmacy
 Role: Principal Investigator
 04/11/11 - 04/11/12 Glycemia, Weight, and Blood Pressure Outcomes After 6 Months
 of Liraglutide Treatment in Patients with Type 2 Diabetes in a
 Real-World Setting; Additional Analyses and Publications

Principal Investigator(s): Diana I. Brixner; Carrie McAdam-Marx
Direct Costs: \$27,000 Total Costs: \$35,829
Novo Nordisk Pharmaceuticals, Inc.
Role: Co-Principal Investigator

05/21/11 - 09/24/11 Glycemia, Weight, and Blood Pressure Outcomes After 6 Months of Liraglutide Treatment in Patients with Type 2 Diabetes in a Real-World Setting
Principal Investigator: Carrie McAdam-Marx
Direct Costs: \$81,300 Total Costs: \$107,885
Novo Nordisk Pharmaceuticals, Inc.
Role: Principal Investigator

07/01/11 - 06/30/13 PORC-Novartis Analytic Fellowship
Principal Investigator(s): Carl V. Asche; Joseph E. Biskupiak; Carrie McAdam-Marx
Direct Costs: \$235,000 Total Costs: \$235,000
Novartis Pharmaceuticals Corporation
Role: Principal Investigator

09/01/11 - 08/31/12 PORC Novartis Outcomes Research Fellowship
Principal Investigator(s): Joseph E. Biskupiak; Carrie McAdam-Marx
Direct Costs: \$147,750 Total Costs: \$147,750
Novartis Pharmaceuticals Corporation
Role: Principal Investigator

01/01/13 - 12/31/15 Pre-Doctorate Training Program in Technology Oriented Comparative Effectiveness Research
Principal Investigator(s): Diana I. Brixner; Michael G. Spigarelli
Direct Costs: \$250,000 Total Costs: \$250,000
PhRMA Foundation
Role: Co-Investigator

05/05/14 - 04/30/16 Comparative Effectiveness of Long-term Glycemic Control and Weight-loss in Patients Treated with Exenatide QW vs. Liraglutide
Principal Investigator: Carrie McAdam-Marx
Direct Costs: \$127,970 Total Costs: \$169,816
ASTRA-ZENECA
Role: Principal Investigator

07/01/14 - 06/30/15 Predictors of glycemic control in patients with type 2 diabetes and mental health conditions
Principal Investigator: Katherine T. Fortenberry
Direct Costs: \$25,000 Total Costs: \$25,000
University of Utah Funding Incentive Seed Grant
Role: Co-Investigator

09/01/14 - 12/31/16 Real-World Glycemic Control and Weight Outcomes after 6 months of Treatment with Pramlintide (Symlin®) in Patients with Type 1 or Type 2 Diabetes
Principal Investigator: Carrie McAdam-Marx
Direct Costs: \$130,200 Total Costs: \$172,775
ASTRA-ZENECA

07/01/15 - 06/30/16 Role: Principal Investigator
 Implementation of Shared Medical Appointments and
 Personalized Diabetes Profiles in an Employer-Based Primary
 Care Clinic
 Principal Investigator: Holly Gurgle
 Direct Costs: \$33,800 Total Costs: \$33,800
 Utah Department of Health
 Role: Co-Investigator

07/01/12 - 05/01/17 Analytic and Outcomes Research Support for ARUP Family
 Medicine Clinic
 Principal Investigator: Carrie McAdam-Marx
 Direct Costs: \$33,900 Total Costs: \$33,900
 ARUP Laboratories
 Role: Principal Investigator

06/01/16 - 05/31/17 Pre-Doctorate Fellowship in Adherence Research
 Direct Costs: \$25,000 Total Costs: \$25,000
 PhRMA Foundation
 Role: Principal Investigator/Pre-Doctorate Student Mentor

VI. TEACHING RESPONSIBILITIES

A. **Education Administration**

2010 - 2015 4th Year Clerkship Primary Preceptor, Pharmacotherapy Outcomes
 Research Elective (PCTH 7538), University of Utah Department of
 Pharmacotherapy

2011 - 2012 Fellowship Program Director, University of Utah Department of
 Pharmacotherapy

2011 Course Master/Course Director, US Healthcare Policy (PCTH
 5114), University of Utah Department of Pharmacotherapy

2012-2016 4th Year Clerkship Primary Preceptor, Real World Evidence and
 Drug Regimen Review (PCTH 7413), University of Utah
 Department of Pharmacotherapy

2012 - 2017 Course Master/Course Director, Graduate Research Seminar I
 (PCTH 6890/7890), University of Utah Department of
 Pharmacotherapy

2013 - 2014 Graduate Program Director, University of Utah Department of
 Pharmacotherapy

2013 - 2015 Course Master/Course Director, Special Problems in
 Pharmacotherapy P&T Competition Preparation Section (PCTH
 6960), University of Utah Department of Pharmacotherapy

2016 - 2017 4th Year Clerkship Primary Preceptor, Clinical Information - Real
 World Evidence (PHARM 7762 replaced PCTH 7413), University
 of Utah Department of Pharmacotherapy

2016 - 2017 Graduate Program Director, University of Utah Department of
 Pharmacotherapy

2016 Co-Course Master, Drug Literature Review & Evaluation I

(PHARM 6240), University of Utah Department of Pharmacotherapy

**B. Courses Taught
University of Utah**

| | |
|-------------|---|
| 2009 - 2013 | PCTH 7538: Outcomes Research Elective Clerkship, 9 students, 66 Student Credit Hours, Pharmacotherapy |
| 2011-2014 | Primary Instructor, PCTH 7950: Independent Study, 2 students, 3 Student Credit Hours, Pharmacotherapy |
| 2011 | Primary Instructor, PCTH 5114: U.S. Health Care Policy, 62 students, 124 Student Credit Hours, Pharmacotherapy |
| 2012-2016 | Primary Instructor, PCTH 7413: Drug Regimen Review and Real-World Outcomes Clerkship, 21 students, 126 Student Credit Hours, Pharmacotherapy |
| 2012 | Primary Instructor, PCTH 6890: Research Seminar I (MS), 2 students, 2 Student Credit Hours, Pharmacotherapy |
| 2012-2017 | Primary Instructor, PCTH 6970: Thesis Research (MS), 15 Student Credit Hours, 1 student, Pharmacotherapy |
| 2013-2017 | Primary Instructor, PCTH 7970: Thesis Research (PhD), 3 Students, 75 Student Credit Hours, Pharmacotherapy |
| 2014 -2016 | Primary Instructor, PCTH 6960: Special Problems in Pharmacotherapy – Managed Care Elective, 36 Student Credit Hours, 18 students, Pharmacotherapy |
| 2014-2016 | Primary Instructor, PCTH 7890: Research Seminar I, 8 Students, 8 Student Credit Hours, Pharmacotherapy |
| 2016 | Primary Instructor, MDCRC 6960: Research Project, 1 student, 8.5 Student Credit Hours, Center for Clinical & Translational Sciences |
| 2016 - 2017 | Primary Instructor, PHARM 7762: Clinical Information Clerkship Real World Evidence, 4 Students, 24 Student Credit Hours, College of Pharmacy |
| 2017 | Co-Primary Instructor, PHARM 6240: Drug Information & Literature Evaluation I, 65 Students, 195 Student Credit Hours, College of Pharmacy |

**C. Didactic Lectures
University of Utah**

| | |
|-------------|---|
| 2009 - 2014 | PCTH 5114 - US Healthcare Policy, Various Lectures per Yearly Syllabus (2009, 2010, 2011, 2014): FDA/Drug Approval, US Healthcare Reform, Right to Try Legislation, Cost of Specialty Drugs |
| 2011 - 2013 | PCTH 7150 - Introduction to Outcomes Research, Cost Benefit Analysis |
| 2011 - 2017 | PCTH 5112 - Profession of Pharmacy, Careers in Outcomes Research |
| 2013 - 2015 | PCTH 6960 - Special Problems in Pharmacotherapy - P&T |

Preparation Class: Introduction to Managed Care, Introduction to Outcomes Research, Evaluating Observational Studies

2015 - 2017 PHARM 7140 - Foundations of Patient-Centered Care, US Healthcare System & Policy, and Quality Improvement

2016 PCTH 7820 - Journal Club. Historical Cohort Analysis Journal Club Example

2016 PHARM 6240 - Drug Literature Review & Evaluation: Biostatistics, Meta-Analysis

D. Small Group Teaching

University of Utah

2010 - 2017 PHARM 7200 - PharmD Seminar - Evaluate 6 Student Seminars per Year

2016 - 2017 PHARM 7151 - Year 1 Recitation - Observational Study Evaluation Session

E. Trainee Supervision

Faculty

2012 - 2016 Advisor/Mentor, Vanessa Stevens, University of Utah. Pharmacotherapy Faculty Mentor
Current Career Activities: Assistant Professor, Division of Epidemiology

2012 - 2017 Advisor/Mentor, Holly Gurgle, University of Utah. Pharmacotherapy Faculty Mentor
Current Career Activities: Clinical Assistant Professor

2016 - 2017 Advisor/Mentor, Elizabeth Unni, Roseman University of Health Sciences. PhRMA Foundation Health Outcomes Research Starter Grant; Research Mentor
Current Career Activities: Faculty, Roseman University of Health Sciences

Fellow

2011 - 2013 Advisor/Mentor, Arati Dahal, University of Utah. Pharmacotherapy Outcomes Research Post-Doctorate Fellow
Last Known Career Activities: Outcomes Researcher, Truven Health Analytics

2011 - 2012 Supervisor, Junji Lin, University of Utah. Analytics Post-Doctorate Fellow, Outcomes Research, Fellowship Director/Advisor
Current Career Activities: Scientist, Pharmerit International

2011 - 2012 Supervisor, Beilei Cai, University of Utah. Outcomes Research Post Doctorate Fellow; Fellowship Director
Current Career Activities: Outcomes Researcher, Novartis Pharmaceuticals

Undergraduate

2013 Advisor/Mentor, Brian Spence, University of Utah. PharmD Student Project Mentor: Association Between Clinically Aligned Pain Assessment and Opioid Use Compared to a Numeric Rating Scale

- Pain Assessment in Hospitalized Patients
Current Career Activities: Clinical Pharmacist, University of Utah Hospitals & Clinics
- 2013 - 2014 Advisor/Mentor, Brad Winter, University of Utah. PharmD Student Project Mentor: Survey of Smoking Cessation Practices among Pharmacists
Current Career Activities: Ambulatory Care Clinical Pharmacist, Intermountain Health Care (PGY2 Completed)
- 2013 - 2014 Advisor/Mentor, Kyle Turner, University of Utah. Assessment of student pharmacist experience at an interprofessional student-run free clinic
Current Career Activities: Clinical Assistant Professor, University of Utah Department of Pharmacotherapy
- 2014 Advisor/Mentor, Greg Hadlock, University of Utah. Diabetes Control in Patients with Diabetes and Mental Health Conditions
Current Career Activities: Clinical Pharmacist, Albuquerque, NM
- 2015 Advisor/Mentor, Simon Rodriquez, University of Utah. Co-Mentor for PSURF Program - Predicting Statin Use after the New ACC/AHA Guidelines for Primary Prevention in a Self-Funded Employer Family Medicine Clinic. AMCP Nexus 2015 Best Student Poster Award.
Current Career Activities: PharmD Student (2017 Candidate), University of Utah
- 2016 Advisor/Mentor, Sarah Kanell, University of Utah. ACCESS Program Mentor
Current Career Activities: Pre-Nursing, University of Utah

F. Graduate Student Committees

- 2009 - 2016 Chair, Weijia Wang, University of Utah, Masters Committee. Thesis Title: Outcomes Evaluation of Statin Treatment in Primary Prevention for Cardiovascular Disease with Time-Dependent LDL-C Goal Attainment. Defense Date: September 19, 2016.
Current Career Activities: HEOR Manager, Boehringer-Ingelheim.
- 2010 - 2012 Member, Matt Higley, University of Utah, Masters Committee. Patients' Perception of the Communication about Medicines Dimension on the HCAHPS Survey Tool. (Pending, research incomplete).
Current Career Activities: Internal Process Control Manager, Central Office at Intermountain Healthcare.
- 2011 - 2013 Member, Jason Braithwaite, University of Utah, Masters Committee. Defining the impact of a central fill pharmacy on outpatient pharmacies in an integrated delivery network using time and motion methodology. Defense Date: June, 2013.
Current Career Activities: Division Director, Clinical Pharmacy Services at Hospital Corporation of America
- 2012 - 2016 Chair, Mukul Singhal, University of Utah, PhD/Doctorate Committee. Co-Chair. Thesis Title: Role of Glycemic Control in Development of Atrial Fibrillation in Veterans with Type 2

- Diabetes Mellitus. Defense Date: August 16, 2016.
Current Career Activities: Research Scientist, HealthCore, Wilmington, DE
- 2013 - Present Chair, Marisa Schauerhamer, University of Utah, PhD/Doctorate Committee. Thesis Title: The Effect of Value-Based Insurance Design on Diabetes Medication Adherence, Glycemic Control and Medical and Pharmacy Costs in Patients with Diabetes in an Employer-Insured Population. Recipient PhRMA Foundation Pre-Doctorate Thesis Award, 2016-17.
Current Career Activities: PhD Student, University of Utah; Research Pharmacist, SCAN Health Plan, Long Beach, CA
- 2013 - 2016 Chair, Eman Bitaji, University of Utah, PhD/Doctorate Committee. Thesis Topic: Clinical Utility of Genomic Profiling in Metastatic Colorectal Cancer. Defense Date: August 18, 2016.
Current Career Activities: Post-Doctorate Fellowship, Pediatrics Pharmacology, University of Utah, Salt Lake City, UT.
- 2014 - 2016 Chair, Jordan King, University of Utah, Masters Committee. MS Project Title: Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared with Enalapril for the Treatment of Heart Failure with Reduced Ejection Fraction. Defense Date: March 17, 2016.
Current Career Activities: Clinical Pharmacy Specialist, Research, Kaiser Permanente, Denver, CO
- 2015 - 2017 Member, Casey Tak, University of Utah, PhD/Doctorate Committee. The Effect of Cost Sharing on Zoster Vaccination.
Current Career Activities: PhD Student & Graduate Research Assistant, University of Utah.

VII. EDITORIAL EXPERIENCE & REVIEWER EXPERIENCE

A. Editorial Experience

2016 - Present Editorial Board for Journal of Managed Care & Specialty Pharmacy

B. Reviewer Experience

Diabetes Obesity & Metabolism

Diabetes Care

Diabetes Technology & Therapeutics

Journal of Healthcare for the Poor and Underserved

Journal of Managed Care & Specialty Pharmacy

Medical Economics

VIII. HONORS AND DISTINCTIONS

A. Awards for Research, Teaching or Service

2010 American Association of Colleges of Pharmacy New Faculty Award

2011 - Present International Society of Clinical Densitometry New Investigator Award

2011 - 2013 Career Development Award in Translational Comparative

- Effectiveness Research, National Cancer Institute
- 2013 - Present National Institute of Health, VA, and Harvard University - Training Institute for Dissemination and Implementation in Health Research Conference Participant July 22-25, Boston MA. Competitive process with 45 of 250 applicants selected to attend.
- 2014, 2016 Excellent Peer Review Recognition, Journal of Managed Care Pharmacy – awarded to top 8% (28 of 359) of reviews
- 2017 American Pharmacists Association, Best Clinical Research Paper for *Pharmacist-provided diabetes management and education via a telemonitoring program*. Shane-McWhorter L, McAdam-Marx C, Lenert L, et al. J Am Pharm Assoc (2003). 2015; 55(5):516-26.

B. Memberships in National and International Societies

- 2005 - Present Member, Academy of Managed Care Pharmacy
- 2005 - Present Member, International Society of Pharmacotherapy and Outcomes Research
- 2008 - Present Professional Member, American Diabetes Association
- 2009 - Present Member, American Association of Colleges of Pharmacy

C. Offices Held in Professional Organizations

- 2011 - 2014 Secretary & Treasurer, Academy of Managed Care Pharmacy, Utah AMCP Affiliate Officer
- 2013 - 2019 Committee Member, Academy of Managed Care Pharmacy, Schools of Pharmacy Relations Committee
- 2014 - 2015 President-Elect, Academy of Managed Care Pharmacy, Utah AMCP Affiliate Officer
- 2015 - 2016 President, Academy of Managed Care Pharmacy, Utah AMCP Affiliate Officer
- 2017 - 2018 Vice-Chair, Editorial Review Board, Academy of Managed Care Pharmacy, Journal of Managed Care & Specialty Pharmacy
- 2016 - 2017 Past President, Academy of Managed Care Pharmacy, Utah AMCP Affiliate Officer

D. Grant Review Committee/Study Section

- 2011 - Present American Association of Colleges of Pharmacy, New Investigator Award, Review Committee

IX. SERVICE

A. University of Utah Health Sciences

- 2011 - 2012 Committee Member, Health Sciences Center, Health Services & Health Behavior Work Group
- 2011 - 2012 Co-Chair, Health Sciences Center, Patient Centered Outcomes Research Interest Group
- 2012 - 2014 Committee Member, Center for Clinical Translational Science, MSCI Curriculum Committee
- 2012 - 2017 Advisory Committee Member, Primary Care Research Network

2015 - 2017 Committee Member, Health Sciences Center, Pharmacy Value Initiative, Project Lead - Diabetes Medication Management and Adherence Project

B. University of Utah Hospitals & Clinics

2015 - 2017 Committee Member, Pharmacy and Therapeutics Committee, University of Utah Health Plan

C. University of Utah College of Pharmacy

2010 - 2017 Committee Member, College of Pharmacy, PharmD Mentoring Committee

2014 - 2017 Committee Member, College of Pharmacy Learning and Teaching Committee

2016 - 2017 Executive Committee Member, School of Medicine, T-32 Interdisciplinary Training Program in Computational Approaches to Diabetes and Metabolism Research. Wendy Chapman & Simon Fisher, PI's.

D. University of Utah Department of Pharmacotherapy

2011 - 2017 Committee Member, Pharmacotherapy, Graduate Program Committee

2014 Chair, Pharmacotherapy, Faculty Search Committee, Research Track

2014 - 2015 Committee Member, Population Health Sciences, Population Health Sciences Graduate Program Development Committee

2014 - 2017 Chair, Pharmacotherapy, Graduate Program Committee

2015 - 2017 Committee Member, Pharmacotherapy, Tenure Track Needs Assessment Task Force

2016 - 2017 Committee Member, Population Health Sciences, PHS Graduate Program Admissions Committee

2016 - 2017 Director, Pharmacotherapy, Director of Graduate Programs

X. ORAL PRESENTATIONS

A. Meeting Presentations

International

2007 Said Q (presenter), Ghate SR, McAdam-Marx C, Brixner DI. Correlation of weight to cardiometabolic risk as identified by ICD-9 diagnosis codes and prescriptions in primary care. ISPOR 12th Annual International Meeting. Arlington, VA.

2007 Brixner DI (presenter), Ghate SR, McAdam-Marx C, Maio V. Analysis of Prescribing Patterns of Antihypertensive Agents (AA) Before and After Publication of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 1st Latin America Conference. Cartagena, Columbia.

2008 LaFleur J (presenter), McAdam-Marx C, Asche CV, Alder S, Sheng

- X, Brixner DI, Silverman S. The risk of clinical vertebral fracture for postmenopausal patients with specific combinations of fracture risk factors in a primary-care setting. National Osteoporosis Foundation, 7th International Symposium on Osteoporosis: Translating Research into Clinical Practice. Washington, DC.
- 2008 Brixner DI (presenter), McAdam-Marx C, Ye XY, Boye K, Fabunmi R, Schroeder B. Real world six month outcomes of patients initiating exenatide in a primary care electronic medical record database. 13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR). Toronto, Canada.

B. Invited/Visiting Professor Presentations

International

- 2009 - Present Late Phase Development of an Antidiabetic Treatment: A Case Study. Late Phase Drug Development World 2009. December 3, 2009. London, UK
- 2013 - Present UK Data – The View from the United States, in Symposium Entitled Fast Access to Big National Healthcare Datasets. International Society of Pharmacoeconomics and Outcomes Research, 18th Annual International Meeting. May 22, 2013. New Orleans, LA

National

- 2010 - Present Late Phase Development of an Antidiabetic Treatment: A Case Study. Late Phase Drug Development World Americas 2010. March 26, 2010. Princeton, NJ

Local/Regional

- 2012 - Present Clinical and Economic Outcomes Associated with a Pharmacist-Coordinated Diabetes Collaborative Care Management Program. Presentation at the Translational Research in Development Seminar, Department of Pediatrics, February 6, 2012
- 2012 - Present Clinical and Economic Outcomes Associated with a Pharmacist-Coordinated Diabetes Collaborative Care Management Program. Presentation at the Department of Pharmacotherapy Faculty Seminar with Brandon Jennings, August 20, 2012
- 2013 - Present Clinical and Economic Outcomes Associated with a Pharmacist-Coordinated Diabetes Collaborative Care Management Program. Presentation at the Utah Health Services Research Conference, February 25, 2013.
- 2014 - Present Population to Patient: How Outcomes Research Can Support Patient-Center Care. University of Utah Department of Pharmacotherapy, Faculty Seminar. January 13, 2014, Salt Lake City, UT
- 2014 - Present Implementation Science in Pharmacy: Mapping the Route from Demonstration to Adoption. University of Arkansas Department of Pharmacy Practice, Department Seminar. January 21, 2014

- 2014 - Present Generating Real-World Evidence for Pharmacotherapy Effectiveness: A Case Study in Diabetes. American Association of Pharmaceutical Sciences, Rocky Mountain Discussion Group. Annual Meeting. August 13, 2014. Missoula MT
- 2015 - Present Value of Pharmacists on Patient Care Teams. University of Utah College of Pharmacy, Pharmacy Ambassadors Advisory Council. April 15, 2015. Salt Lake City, UT
- 2016 - Present Pharmacists Value in Employer-Based Primary Care. University of Utah College of Pharmacy, All College Seminar. April 14 2016, Salt Lake City, UT. Co-Presented with H. Gurgle.

C. Peer-Reviewed Presentations

International

- 2016 - Present Differences in common medication adherence measurements illustrated through a diabetes outcomes study. European Health Psychology Society (EHPS) conference 2016. August 23-27, 2016. Aberdeen, UK.

Local/Regional

- 2014 - Present Is There a Pharmacist in the (Medical) Home? The Impact of Pharmacist-Led Diabetes Collaborative Drug Therapy Management on Patient Outcomes. August 14, 2014, Skaggs Biomedical Research Symposium. Missoula, MT

